Successful retreatment with infliximab in patients with prior severe infusion reactions

Imad Uthman; Zahi Touma; Jinane El-Sayyad; Fares Zaitoun

doi:10.1007/s10067-005-0029-9

Successful retreatment with infliximab in patients with prior severe infusion reactions

Clin Rheumatol. 2006 Jul;25(4):540-1. doi: 10.1007/s10067-005-0029-9. Epub 2005 Oct 7.

Authors

Imad Uthman¹, Zahi Touma, Jinane El-Sayyad, Fares Zaitoun

Affiliation

¹ Division of Rheumatology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon. iuthman@aub.edu.lb

PMID: 16211336
DOI: 10.1007/s10067-005-0029-9

Abstract

Infusion of the antitumor necrosis factor-alpha chimeric monoclonal antibody infliximab can be associated with the development of severe infusion reactions (IR) during retreatment. We present the case of two rheumatoid arthritis patients with a history of severe acute IR to infliximab who subsequently underwent successful infusion using a prophylactic treatment with a combination of H1 and H2 receptor blockers, hydrocortisone, and diphenhydramine.

Publication types

Case Reports

MeSH terms

Adult
Aged
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Diphenhydramine / therapeutic use*
Drug Administration Schedule
Drug Therapy, Combination
Female
Histamine H1 Antagonists / therapeutic use*
Histamine H2 Antagonists / therapeutic use*
Humans
Hydrocortisone / therapeutic use*
Infliximab
Infusions, Intravenous / adverse effects
Retreatment / methods
Treatment Outcome

Substances

Antibodies, Monoclonal
Histamine H1 Antagonists
Histamine H2 Antagonists
Diphenhydramine
Infliximab
Hydrocortisone